Business Wire

Universal Electronics to Launch New Voice Remotes for RDK Platform at RDK Tech Summit

12.7.2022 10:15:00 EEST | Business Wire | Press release

Share

Universal Electronics Inc. (UEI) (NASDAQ:UEIC), the world leader in universal control technology for entertainment and smart home, at the 2022 RDK Tech Summit has announced the release of two new voice remotes for RDK. RDK is one of the leading broadband and pay-tv platforms for the cable industry, with the support of hundreds of partner companies and deployed by more than 30 operators.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005949/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Universal Electronics to Launch New Voice Remotes for RDK Platform at RDK Tech Summit (Photo: Business Wire)

UEI has shipped over 75 million RDK remote controls to date, with leading operators around the globe, making UEI a market leader in RDK control solutions.

In 2017, the National Academy of Television Arts & Sciences awarded UEI a Technology & Engineering Emmy® Award for its contribution to “Contextual Voice Navigation for Discovering and Interacting with TV Content,” recognizing UEI’s innovator role in the development of the RDK platform.

With the introduction of two new remote-control designs, UEI is expanding its footprint to make it simple for the operators in the RDK community to expand their offering with features that consumers have come to expect from pay-tv services, such as voice control and universal operation of TV sets regardless of the brand.

UEI is collaborating closely with the RDK community to integrate voice and universal control as part of the RDK Accelerator Program – an initiative launched by the RDK community to make it easier for operators to adopt the RDK platform and launch products. UEI’s new RDK remotes serve the same purpose: Since the remotes are pre-integrated, operators can pick one and rest assured it will work with any RDK Accelerator set-top box, relieving them of tedious integration effort and ensuring a short time to market.

Steve Gutman, SVP of Global Sales for Video Service Providers at UEI, said: “We are looking forward to helping customers around the world on the RDK platform to include advanced convenience features such as voice control and automated set-up of their TV and audio devices including soundbars and AV receivers.”

The two new RDK platform remotes UEI is launching at RDK Summit are named “UEI Tatlow” and “UEI Logan.” “UEI Tatlow” is a high-performance voice remote with a premium keypad and optional full backlight, making it easy for people to use it in the dark. “UEI Logan” is a premium voice remote with a unique look and feel including a unibody keypad that is easy to clean.

Both remotes are designed to control live, recorded, and on-demand TV as well as streaming video, and are optionally equipped with QuickSet, the world’s only automated set-up and control experience for home entertainment and smart home devices.

To schedule a meeting with us at RDK Summit visit here

About Universal Electronics Inc.

Universal Electronics Inc. (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices; designs, develops, manufactures, ships and supports hardware and software control and sensor technology solutions. UEI partners with many Fortune 500 customers, including Comcast, Vivint Smart Home, Samsung, LG, Sony, and Daikin to serve video, telecommunications, security service providers, television, smart home, and HVAC system manufacturers. For over 35 years, UEI has been pioneering breakthrough innovations such as voice control and QuickSet cloud, the world’s leading platform for automated set-up and control of devices in the home. For more information visit www.uei.com

About RDK Management:

RDK Management is an open-source consortium that manages RDK for the global community. RDK is an open-source software platform for the connected home that standardizes core functions used in broadband, video, and IoT devices. It enables operators to manage their devices; control their business models; and customize their apps, UIs and data analytics to improve the customer experience and drive business results. The RDK community is comprised of more than 500 companies including: CPE manufacturers, SoC vendors, software developers, system integrators, and service providers. For more information on the tools, training, and events provided by RDK Management, please visit: www.rdkcentral.com.

All trademarks appearing herein are the property of their respective owners.
Quickset® is a trademarks of Universal Electronics Inc.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release; the purchasing by UEI customers of the UEI RDK products identified in this release in the quantities anticipated by management; the continued penetration and growth of UEI voice recognition technology and other products and consumer technologies identified in this release; and other factors described in UEI’s filings with the Securities and Exchange Commission. The actual results that UEI achieves may differ materially from any forward-looking statement due to such risks and uncertainties. UEI undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Eva Delgado
Universal Electronics Inc.
eva.delgado@uei.com
714-987-8209

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye